Watchdog says expensive cancer drugs not delivering
Value for money criteria met by only one of 20 new drugs that had an initial asking price of €500 million
Just one of 20 new cancer drugs examined by the state’s medicines watchdog was considered value for money, according to a new assessment by the body.
Independent journalism every day
With digital access you can read The Business Post whenever, wherever, and however you want.
- Unlimited access to all sections of The Business Post on desktop, tablet and mobile.
- Breaking news, comment and analysis from the best Business Post writers seven days a week.
- Live blogs of major news events
- Videos and podcasts from some of the industry's most respected journalists such as Tom Lyons, Susan Mitchell and Ian Guider
- Access to The Business Post's extensive archive
